Document Detail

Effects of eicosapentaenoic acid on blood pressure, cell membrane fatty acids, and intracellular sodium concentration in essential hypertension.
MedLine Citation:
PMID:  11675948     Owner:  NLM     Status:  MEDLINE    
This study was designed to clarify the effects of orally administered eicosapentaenoic acid (EPA) on blood pressure, intracellular sodium content, and cell membrane fatty acid composition in patients with essential hypertension. After a 4-week run-in period, a study group of 17 male patients was assigned to an 8-week treatment with EPA (2.7 g/day) or placebo in a randomized, double-blind fashion with a crossover at week 4. Systolic blood pressure (SBP) was lower after treatment with EPA than after treatment with placebo (152.9+/-17.3 vs. 162.6+/-20.6 mmHg; p<0.01), while diastolic blood pressure was not statistically different. Compared with the placebo treatment, EPA supplementation resulted in a decrease in intraerythrocyte sodium content (R-Na; 11.17+/-0.63 vs. 10.44+/-1.28 nmol/l cells; p<0.05) accompanied by an increase (p<0.001) in erythrocyte membrane EPA content. The increase in membrane EPA content was related to the decrease in SBP (r=-0.52, p<0.05) and the decrease in R-Na (r=-0.57, p<0.02) during EPA treatment. The decrease in R-Na correlated positively with the decrease in SBP (r=0.54, p<0.05), and correlated negatively with the change in Na+-K+ ATPase activity (r= -0.59, p<0.02). However, the change in Na+-K+ ATPase activity did not directly correlate with the change in membrane EPA content. In conclusion, oral EPA supplementation increased membrane EPA content and reduced SBP in patients with essential hypertension. Based on the association between the increase in membrane EPA content and the decrease in intracellular sodium concentration, EPA may lower blood pressure by altering the activities of the membrane sodium transport systems.
T Miyajima; T Tsujino; K Saito; M Yokoyama
Related Documents :
7990088 - Nutritional factors in blood pressure.
1987008 - An overview of randomized trials of sodium reduction and blood pressure.
2318418 - The case for dietary management of the older hypertensive.
663768 - Hypotensive anesthesia for spinal fusion with sodium nitroprusside.
25010588 - Differential phenotype profile between main right ventricular chamber and outflow tract...
18432188 - Common genetic variants in the chromogranin a promoter alter autonomic activity and blo...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  24     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-10-24     Completed Date:  2002-03-22     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  537-42     Citation Subset:  IM    
First Department of Internal Medicine, Kobe University School of Medicine, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arachidonic Acids / administration & dosage*
Blood Pressure / drug effects*
Cell Membrane / chemistry
Cross-Over Studies
Double-Blind Method
Erythrocytes / chemistry,  enzymology
Fatty Acids / analysis*
Hypertension / drug therapy*,  metabolism
Middle Aged
Plant Oils / administration & dosage
Regression Analysis
Sodium / analysis*
Sodium-Potassium-Exchanging ATPase / metabolism
Reg. No./Substance:
0/Arachidonic Acids; 0/Fatty Acids; 0/Plant Oils; 7440-23-5/Sodium; EC ATPase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima Stu...
Next Document:  Biosynthesis and secretion of adrenomedullin and proadrenomedullin N-terminal 20 peptide in a rat mo...